CIGB 550 E7

Drug Profile

CIGB 550 E7

Alternative Names: Human papillomavirus vaccine - Heber Biotec

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical cancer

Most Recent Events

  • 23 Feb 2016 Preclinical trials in Cervical cancer in Cuba (SC) prior to February 2016
  • 23 Feb 2016 Pharmacodynamic data from a preclinical trial in cancer released by Center for Genetic Engineering and Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top